Cepheid
Suzette Chance has extensive experience in regulatory affairs and clinical research within the in vitro diagnostics sector. Currently serving as Vice President of Regulatory Affairs at Cepheid since October 2017, Suzette previously held senior roles at Great Basin Scientific, Immucor GTI Diagnostics, Gen-Probe/Hologic, Genetic Testing Institute, and Dade Behring. Expertise encompasses regulatory strategy, clinical study design, product innovation, and compliance, with a background in leading cross-functional teams and developing new product strategies. Educational qualifications include a Ph.D. in Biochemistry from Johns Hopkins University, a Post Doctoral Fellowship in Biochemistry and Cell Biology from the same institution, and current participation in the RAPS Regulatory Affairs Executive Development Program at Northwestern University.
This person is not in any teams
This person is not in any offices
Cepheid
10 followers
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.